UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000024222
Receipt number R000027559
Scientific Title Comparison of ability of supraglottic airway(SGA) for children and infants under general anesthesia
Date of disclosure of the study information 2016/09/30
Last modified on 2019/05/28 20:37:43

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Comparison of ability of supraglottic airway(SGA) for children and infants under general anesthesia

Acronym

Comparison of ability of SGA for children and infants under general anesthesia

Scientific Title

Comparison of ability of supraglottic airway(SGA) for children and infants under general anesthesia

Scientific Title:Acronym

Comparison of ability of SGA for children and infants under general anesthesia

Region

Japan


Condition

Condition

Patient who undergo general anesthesia with SGA

Classification by specialty

Anesthesiology Child

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate SGA performance in insertion for children and infants

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

Sealing Pressure

Key secondary outcomes

Insertion Success time, Postoperative pharyngeal pain, hoarseness , Subjective difficulty of insertion, Placement of SGA(bronchoscopic view), complication


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Single blind -participants are blinded

Control

Active

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Device,equipment

Interventions/Control_1

We insert Ambu Auragain in paitent mouth by standard method from center part, in completely deflated. If there is a resistance, we turn the sevice gently, or chin-up. After the device was detained at the good position, we inflate cuff.
We use Ambu Auragain to ventilate adeqate respiration during surgery. After surgery finished, we stop inhalation anesthesia and remove the Ambu Auragain Spontaneous breathing restart enough.

Interventions/Control_2

We insert i-gel in paitent mouth by standard method from center part, in completely deflated. If there is a resistance, we turn the sevice gently, or chin-up.
We use i-gel to ventilate adeqate respiration during surgery. After surgery finished, we stop inhalation anesthesia and remove the i-gel Spontaneous breathing restart enough.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

1 years-old <

Age-upper limit

12 years-old >

Gender

Male and Female

Key inclusion criteria

Patient who undergo general anesthesia with SGA

Key exclusion criteria

Emergent operation, Upper respiratory tract infection, Pulmonary disease, Medicalhistory or predictor of difficult airway management, Airway malformation, High risk of gastric regurgitation or vomitting, surgical technique that intubation needs

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Rika
Middle name
Last name Nakayama

Organization

Kanagawa childrens medical center

Division name

Anesgthesiology

Zip code

2328555

Address

2-138-4Mutsukawa, minami-ku Yokohama city

TEL

045-711-2351

Email

rnakayama@kcmc.jp


Public contact

Name of contact person

1st name Rika
Middle name
Last name Nakayama

Organization

Kanagawa childrens medical center

Division name

Anesgthesiology

Zip code

2328555

Address

2-138-4Mutsukawa, minami-ku Yokohama city

TEL

045-711-2351

Homepage URL


Email

rnakayama@kcmc.jp


Sponsor or person

Institute

Kanagawa childrens medical center

Institute

Department

Personal name



Funding Source

Organization

Kanagawa childrens medical center

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kanagawa childrens medical center

Address

2-138-4Mutsukawa, minami-ku Yokohama city

Tel

045-711-2351

Email

R-nakayama@guitar.ocn.ne.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 09 Month 30 Day


Related information

URL releasing protocol

UMIN000024222

Publication of results

Published


Result

URL related to results and publications

https://www.ncbi.nlm.nih.gov/pubmed/30950904

Number of participants that the trial has enrolled

100

Results

The OLP immediately after insertion was lower for the AuraGain than for the i-gel (17.1 vs. 23.0cmH2O; mean difference: -5.9cmH2O; 95% confidence interval: -8.5 to -3.3cmH2O; P=0.98 and <0.001 for noninferiority and superiority, respectively). The first-attempt success rate (AuraGain, 96% vs. i-gel, 90%; P=0.44) was comparable between the devices. The incidence of blood staining was lower (AuraGain, 6% vs. i-gel, 0%; P=0.012).

Results date posted

2019 Year 05 Month 28 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

The patients characteristics were comparable between the groups.

Participant flow

A total of 100 patients were included in this trial.
Two patients were excluded after randomisation.

Adverse events

The blood staining rate was lower and the time to insertion was shorter in the i-gel than in the AuraGain groups. The incidence of intra-operative airway obstruction was higher in the i-gel group, but the difference was not statistically significant.

Outcome measures

The oropharyngeal leak pressure (noninferiority hypothesis)
The oropharyngeal leak pressure (superiority hypothesis)
Time to insertion
First attempt success rate
Ease of SGA insertion
The incidence of airway obstraction
The ease of gastric tube insertion
Adverse events

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2016 Year 09 Month 01 Day

Date of IRB

2016 Year 09 Month 12 Day

Anticipated trial start date

2016 Year 09 Month 12 Day

Last follow-up date

2017 Year 03 Month 31 Day

Date of closure to data entry

2017 Year 04 Month 05 Day

Date trial data considered complete

2017 Year 06 Month 30 Day

Date analysis concluded

2017 Year 07 Month 31 Day


Other

Other related information



Management information

Registered date

2016 Year 09 Month 29 Day

Last modified on

2019 Year 05 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027559


Research Plan
Registered date File name
2017/01/25 プロトコール試案98-03.doc

Research case data specifications
Registered date File name

Research case data
Registered date File name